<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ADRENALIN- epinephrine injection </strong><br>Par Pharmaceutical, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ADRENALIN safely and effectively. See full prescribing information for ADRENALIN.<br><br> ADRENALIN (epinephrine injection) 1 mg/mL (1:1000)<br> 1mL vial: for intramuscular, subcutaneous, and intraocular use<br> 30 mL vial: for intramuscular and subcutaneous use<br> Initial U.S. Approval: 1939</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Adrenalin<span class="Sup">®</span> is a non-selective alpha and beta adrenergic agonist indicated for: </p>
<dl>
<dt>•</dt>
<dd>Emergency treatment of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (Type 1), including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (Adrenalin<span class="Sup">®</span> 1 mL and 30 mL vials) (<a href="#S1.1">1.1</a>)</dd>
<dt>•</dt>
<dd>Induction and maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> during intraocular surgery (Adrenalin<span class="Sup">®</span> 1 mL vial only) (<a href="#S1.2">1.2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> </span>(Adrenalin<span class="Sup">®</span> 1 mL and 30 mL vials):<dl>
<dt>•</dt>
<dd>
<span class="Italics">Adults and Children 30 kg (66 lbs) or more</span>: 0.3 to 0.5 mg (0.3 to 0.5 mL) intramuscularly or subcutaneously into anterolateral aspect of the thigh every 5 to 10 minutes as necessary (<a href="#S2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Children 30 kg (66 lbs) or less</span>: 0.01 mg/kg (0.01 mL/kg), up to 0.3 mg (0.3 mL), intramuscularly or subcutaneously into anterolateral aspect of the thigh every 5 to 10 minutes as necessary (<a href="#S2.1">2.1</a>)</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Underline">Intraocular surgery </span>(Adrenalin<span class="Sup">®</span> 1 mL vial only): Dilute 1 mL with 100 to 1000 mL of an ophthalmic irrigation fluid, for ophthalmic irrigation or intracameral injection (<a href="#S2.2">2.2</a>)</dd>
</dl></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Injection: 1 mg/mL (1:1000), 1 mL single-use vials and 30 mL multiple-dose vials (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Do not use 30 mL vial for ophthalmic indication (<a href="#S5.1">5.1</a>)</dd>
<dt>•</dt>
<dd>Undiluted ophthalmic administration: associated with corneal endothelial damage (<a href="#S5.2">5.2</a>)</dd>
<dt>•</dt>
<dd>Do not inject into buttocks, digits, hands, or feet (<a href="#S5.3">5.3</a>)</dd>
<dt>•</dt>
<dd>May aggravate <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> or produce <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, particularly in patients with underlying heart disease, administer with caution when used intramuscularly or subcutaneously (<a href="#S5.4">5.4</a>)</dd>
<dt>•</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, Parkinson's disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> are at greater risk of having adverse reactions when used intramuscularly or subcutaneously (<a href="#S5.4">5.4</a>)</dd>
<dt>•</dt>
<dd>Presence of sulfite in this product should not deter use for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (<a href="#S5.5">5.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reactions to systemically administered epinephrine include <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, apprehensiveness, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and respiratory difficulties. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, including fatal <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, rapid rises in blood pressure producing <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, and angina have occurred (<a href="#S6.1">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Sympathomimetic agents: possible additive effects (<a href="#S7">7</a>)</dd>
<dt>•</dt>
<dd>Cardiac glycosides, halogenated hydrocarbon anesthetics, or diuretics: observe for development of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> (<a href="#S7">7</a>)</dd>
<dt>•</dt>
<dd>Tricyclic antidepressants, MAO inhibitors, levothyroxine sodium, and certain antihistamines: potentiate effects of epinephrine (<a href="#S7">7</a>)</dd>
<dt>•</dt>
<dd>Beta-adrenergic blocking drugs: antagonize the cardiostimulating and bronchodilating effects of epinephrine (<a href="#S7">7</a>)</dd>
<dt>•</dt>
<dd>Alpha-adrenergic blocking drugs: antagonize the vasoconstricting and hypertensive effects of epinephrine (<a href="#S7">7</a>)</dd>
<dt>•</dt>
<dd>Ergot alkaloids may reverse the pressor response to epinephrine (<a href="#S7">7</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally (<a href="#S8.1">8.1</a>,<a href="#S8.5"> 8.5</a>) </p></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1    INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> (Adrenalin<span class="Sup">®</span> 1 mL single-use and 30 mL multiple-dose vials)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Induction and Maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> during Intraocular Surgery (Adrenalin<span class="Sup">®</span> 1 mL single-use vial only)</a></h2>
<h1><a href="#section-2" class="toc">2    DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> (Adrenalin<span class="Sup">®</span> 1 mL single-use and 30 mL multiple-dose vials)</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Induction and Maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> during Intraocular Surgery (Adrenalin<span class="Sup">®</span> 1 mL single-use vial only)</a></h2>
<h1><a href="#section-3" class="toc">3    DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4    CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5    WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Potential for Ophthalmic Injury from Adrenalin<span class="Sup">®</span> 30 mL multiple-dose vial</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Injury with Undiluted Intraocular Solution</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Incorrect Locations of Injection</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  Disease Interactions</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> Associated with Sulfite</a></h2>
<h1><a href="#section-6" class="toc">6    ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Adverse Reactions Associated with Intramuscular/Subcutaneous Use (for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>)</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Adverse Reactions Associated with Intraocular Use (for <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span>)</a></h2>
<h1><a href="#section-7" class="toc">7    DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8    USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE </a></h1>
<h1><a href="#section-10" class="toc">11    DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12    CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13    NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14     CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1  Induction and Maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> during Intraocular Surgery</a></h2>
<h1><a href="#section-14" class="toc">16    HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17    PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1    INDICATIONS AND USAGE</h1>
<p class="First">Adrenalin<span class="Sup">®</span> is available as a single-use 1 mL vial and a multiple-use 30 mL vial. The 1 mL vial is for intramuscular, subcutaneous, and intraocular use. The 30 mL vial is for intramuscular and subcutaneous use only, and is NOT FOR OPHTHALMIC USE.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> (Adrenalin<span class="Sup">®</span> 1 mL single-use and 30 mL multiple-dose vials)</h2>
<p class="First">Emergency treatment of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (Type I), including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, which may result from <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to insect <span class="product-label-link" type="condition" conceptid="4083844" conceptname="Bee sting">stings</span>, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or exercise-induced <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. The signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, thready or unobtainable pulse associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, involuntary voiding, airway <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the eyelids, lips, and tongue.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Induction and Maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> during Intraocular Surgery (Adrenalin<span class="Sup">®</span> 1 mL single-use vial only)</h2>
<p class="First">Induction and maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> during intraocular surgery.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2    DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> (Adrenalin<span class="Sup">®</span> 1 mL single-use and 30 mL multiple-dose vials)</h2>
<p class="First">Inject Adrenalin<span class="Sup">®</span> intramuscularly or subcutaneously into the anterolateral aspect of the thigh. The injection may be repeated every 5 to 10 minutes as necessary. For intramuscular administration, use a needle long enough (at least 1/2 inch to 5/8 inch) to ensure the injection is administered into the muscle. Monitor the patient clinically for the severity of the <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> and potential cardiac effects of the drug, with repeat doses titrated to effect. Do not administer repeated injections at the same site, as the resulting <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> may cause tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.</p>
<p>Inspect visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dc72d085-4dd9-4b7a-a90d-036874044ab5"></a><a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Underline">Adults and Children 30 kg (66 lbs) or more</span>: 0.3 to 0.5 mg (0.3 mL to 0.5 mL) of undiluted Adrenalin<span class="Sup">®</span> administered intramuscularly or subcutaneously in the anterolateral aspect of the thigh, up to a maximum of 0.5 mg (0.5 mL) per injection, repeated every 5 to 10 minutes as necessary. Monitor clinically for reaction severity and cardiac effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2fb36ff9-65e5-4637-bbcc-b3263a1c4371"></a><a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Underline">Children less than 30 kg (66 lbs)</span>: 0.01 mg/kg (0.01 mL/kg) of undiluted Adrenalin<span class="Sup">®</span> administered intramuscularly or subcutaneously in the anterolateral aspect of the thigh, up to a maximum of 0.3 mg (0.3 mL) per injection, repeated every 5 to 10 minutes as necessary. Monitor clinically for reaction severity and cardiac effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Induction and Maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> during Intraocular Surgery (Adrenalin<span class="Sup">®</span> 1 mL single-use vial only)</h2>
<p class="First">Adrenalin<span class="Sup">®</span> must be diluted prior to intraocular use. Dilute 1 mL of Adrenalin<span class="Sup">®</span> 1 mg/mL (1:1000) in 100 to 1000 mL of an ophthalmic irrigation fluid to create an epinephrine concentration of 1:100,000 to 1:1,000,000 (10 mcg/mL to 1 mcg/mL). Use the irrigating solution as needed for the surgical procedure.</p>
<p>After dilution in an ophthalmic irrigating fluid, Adrenalin<span class="Sup">®</span> may also be injected intracamerally as a bolus dose of 0.1 mL at a dilution of 1:100,000 to 1:400,000 (10 mcg/mL to 2.5 mcg/mL).</p>
<p>Inspect visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter.</p>
<p>Note:  The Adrenalin<span class="Sup">®</span> 30 mL multiple-dose vial is not for ophthalmic use. USE ONLY THE ADRENALIN 1 ML SINGLE-USE VIAL FOR OPHTHALMIC USE.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3    DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Adrenalin<span class="Sup">®</span> 1 mg/mL (1:1000) epinephrine injection, 1 mL solution in a single-use clear glass vial and 30 mL solution in a multiple-dose amber glass vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4    CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5    WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Potential for Ophthalmic Injury from Adrenalin<span class="Sup">®</span> 30 mL multiple-dose vial</h2>
<p class="First">The Adrenalin<span class="Sup">®</span> 30 mL multiple-dose vial is not for ophthalmic use because it contains chlorobutanol which may be harmful to the corneal endothelium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Injury with Undiluted Intraocular Solution</h2>
<p class="First">The Adrenalin<span class="Sup">®</span> 1 mL single-use vial, while it does not contain chlorobutanol, <span class="Bold">must</span> be diluted before intraocular use. Epinephrine containing sodium bisulfite has been associated with corneal endothelial damage when used in the eye at undiluted concentrations (1 mg/mL) [<span class="Italics">see<a href="#S2.2"> Dosage and Administration (2.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Incorrect Locations of Injection</h2>
<p class="First">Injection into the anterolateral aspect of the thigh (vastus lateralis muscle) is the most appropriate location for administration because of its location, size, and available blood flow. Injection into (or near) smaller muscles, such as in the deltoid, is not recommended due to possible differences in absorption associated with this use.</p>
<p>Do not administer repeated injections of epinephrine at the same site, as the resulting <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> may cause tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.</p>
<p><span class="Bold">Do not inject into buttock. </span>Injection into the buttock may not provide effective treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and has been associated with the development of <span class="product-label-link" type="condition" conceptid="433696" conceptname="Gas gangrene">gas gangrene</span>. Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower this risk.</p>
<p><span class="Bold">Do not inject into digits, hands, or feet. </span>Epinephrine is a strong vasoconstrictor. Accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area and has been associated with tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  Disease Interactions</h2>
<p class="First">Some patients may be at greater risk for developing adverse reactions after systemic epinephrine administration. Despite these concerns, the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1e9949bd-2304-479d-896a-b282915d6de9"></a><a name="section-5.4.1"></a><p></p>
<p class="First"><span class="Underline">Patients with Heart Disease</span></p>
<p>Epinephrine should be administered with caution in patients who have heart disease, including patients with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, coronary artery or organic heart disease, cerebrovascular disease, or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. In such patients, or in patients who are on drugs that may sensitize the heart to <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, epinephrine may precipitate or aggravate <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> as well as produce <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>. [<span class="Italics">see<a href="#S7"> Drug Interactions (7) </a>and<a href="#S6.1"> Adverse Reactions (6.1)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3b542e39-7d3e-4ca8-b97e-84148e7f6cf4"></a><a name="section-5.4.2"></a><p></p>
<p class="First"><span class="Underline">Other Patients and Diseases</span></p>
<p>Epinephrine should be administered with caution to patients with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, Parkinson's disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, elderly individuals, and pregnant women. Patients with Parkinson's disease may experience <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span> or notice a temporary worsening of symptoms. Diabetic patients may experience transient increases in blood sugar.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> Associated with Sulfite</h2>
<p class="First">Adrenalin<span class="Sup">®</span> contains sodium bisulfite which may cause mild to severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in susceptible individuals. However, the presence of bisulfite in this product should not preclude its use for the treatment of serious allergic or other emergency situations even if the patient is sulfite-sensitive, as the alternatives to using epinephrine in a life-threatening situation may not be satisfactory.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6    ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Adverse Reactions Associated with Intramuscular/Subcutaneous Use (for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>)</h2>
<p class="First">Common adverse reactions to systemically administered epinephrine include <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, apprehensiveness, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and respiratory difficulties. These symptoms occur in some persons receiving therapeutic doses of epinephrine, but are more likely to occur in patients with heart disease, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4)</a></span>].</p>
<p>Due to the lack of randomized, controlled clinical trials of epinephrine for the treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, the true incidence of adverse reactions associated with the systemic use of epinephrine is difficult to determine. Adverse reactions reported in observational trials, case reports, and studies are listed below by body system:</p>
<p><span class="Underline">Cardiovascular</span>: angina, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, and ventricular ectopy.</p>
<p>Angina may occur in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4)</a></span>].</p>
<p><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, including fatal <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, have occurred, particularly in patients with underlying organic heart disease or patients receiving drugs that sensitize the heart to <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4)</a></span>].</p>
<p>Rapid rises in blood pressure associated with epinephrine use have produced <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, particularly in elderly patients with cardiovascular disease [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4)</a></span>].</p>
<p><span class="Underline">Respiratory</span>: respiratory difficulties.</p>
<p><span class="Underline">Neurological</span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> , <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> , <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> , <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> , impaired memory , <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> , <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> , panic, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> , <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> , <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p><span class="Underline">Psychiatric</span>: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, apprehensiveness, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.</p>
<p><span class="Underline">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Underline">Other</span>:</p>
<p>Patients with Parkinson's disease may experience <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span> or a temporary worsening of symptoms [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4)</a></span>].</p>
<p>Diabetic patients may experience transient increases in blood sugar [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4)</a></span>].</p>
<p>Accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area [<span class="Italics">see<a href="#S5.3"> Warnings and Precautions (5.3)</a></span>]. Adverse events experienced as a result of an injection into these areas include increased heart rate, local reactions including injection site <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, and tissue loss, or injury at the injection site resulting in <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, discoloration, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="4154739" conceptname="Bone injury">skeletal injury</span>.</p>
<p>Injection into the buttock has resulted in cases of <span class="product-label-link" type="condition" conceptid="433696" conceptname="Gas gangrene">gas gangrene</span> [<span class="Italics">see<a href="#S5.3"> Warnings and Precautions (5.3)</a></span>].</p>
<p><span class="Underline">Skin</span>: <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Adverse Reactions Associated with Intraocular Use (for <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span>)</h2>
<p class="First">Epinephrine containing sodium bisulfite has been associated with corneal endothelial damage when used in the eye at undiluted concentrations (1 mg/mL).</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7    DRUG INTERACTIONS</h1>
<p class="First">Epinephrine should be administered cautiously to patients taking other sympathomimetic agents because of the possibility of additive effects.</p>
<p>Patients who are concomitantly receiving cardiac glycosides, digitalis, diuretics, quinidine, and other antiarrhythmics should be observed carefully for the development of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4) </a>and<a href="#S6.1"> Adverse Reactions (6.1)</a></span>].</p>
<p>Administer epinephrine cautiously to patients receiving halogenated hydrocarbon general anesthetics, such as halothane, as coadministration may result in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.</p>
<p>The effects of epinephrine may be potentiated by tricyclic antidepressants such as imipramine, monoamine oxidase inhibitors (MAOI), levothyroxine sodium, and certain antihistamines, notably diphenhydramine, tripelannamine, and dexchlorpheniramine.</p>
<p>The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta-adrenergic blocking drugs, such as propranolol.</p>
<p>The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine.</p>
<p>Ergot alkaloids may reverse the pressor effects of epinephrine.</p>
<p>Epinephrine should not be used to counteract <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result in further lowering of blood pressure.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8    USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_d5c9a33a-c7c4-4c17-98e5-24789c337fec"></a><a name="section-8.1.1"></a><p></p>
<p class="First">Teratogenic Effects: Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Epinephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (fetal <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span>, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>, or both). Epinephrine is teratogenic in rabbits, mice and hamsters dosed during organogenesis.</p>
<p>Epinephrine has been shown to have teratogenic effects (including <span class="product-label-link" type="condition" conceptid="4218764" conceptname="Gastroschisis">gastroschisis</span> and embryonic lethality) when administered subcutaneous in rabbits at approximately 15 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m<span class="Sup">2</span> basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days).</p>
<p>In mice, teratogenic effects (including embryonic lethality) were observed at approximately 3 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m<span class="Sup">2</span> basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). These effects were not seen in mice at approximately 2 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m<span class="Sup">2</span> basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days).</p>
<p>In hamsters, teratogenic effects were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m<span class="Sup">2</span> basis at a maternal subcutaneous dose of 0.5 mg/kg/day for 4 days).</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Use with caution during labor and delivery. Although epinephrine improves maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, it may result in uterine <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, decreased uterine blood flow, and fetal <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether epinephrine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when epinephrine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Clinical use data support weight-based dosing for treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> in pediatric patients, and other reported clinical experience with the use of epinephrine suggests that the adverse reactions seen in children are similar in nature and extent to those both expected and reported in adults.</p>
<p>The safety and effectiveness of epinephrine (at a dilution of 1:100,000 to 1:400,000) for induction and maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> during intraocular surgery have been established in pediatric patients. Use of Adrenalin<span class="Sup">®</span> for induction and maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> during intraocular surgery in pediatric patients is supported by adequate and well controlled studies in adults and uncontrolled studies in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies for the treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have not been performed in subjects aged 65 and over to determine whether they respond differently from younger subjects. However, other reported clinical experience with use of epinephrine for the treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. Therefore, for the treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, consider starting with a lower dose to take into account potential concomitant disease or other drug therapy.</p>
<p>For induction and maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> during intraocular surgery, no overall differences have been observed between elderly and other patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE </h1>
<p class="First">Overdosage of epinephrine may produce extremely elevated arterial pressure, which may result in cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, particularly in elderly patients. Overdosage may also result in <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> because of peripheral vascular constriction together with cardiac stimulation. Treatment consists of a rapidly acting α-adrenergic blocking drug and respiratory support.</p>
<p>Epinephrine is rapidly inactivated in the body and treatment following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with epinephrine is primarily supportive. If necessary, pressor effects may be counteracted by rapidly acting vasodilators or α-adrenergic blocking drugs. If prolonged <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> follows such measures, it may be necessary to administer another pressor drug.</p>
<p>Epinephrine overdosage can also cause transient <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> followed by <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and these may be accompanied by potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">Premature ventricular contractions</span> may appear within one minute after injection and may be followed by multifocal <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (prefibrillation rhythm). Subsidence of the ventricular effects may be followed by <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> and occasionally by <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>. Treatment of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> consists of administration of a beta-adrenergic blocking drug such as propranolol.</p>
<p>Overdosage sometimes results in extreme <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> and <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> of the skin, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> due to elevated blood lactic acid levels, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. Suitable corrective measures must be taken in such situations.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11    DESCRIPTION</h1>
<p class="First">Adrenalin<span class="Sup">®</span> (epinephrine injection, USP) is a clear, colorless, sterile solution containing 1 mg/mL (1:1000) epinephrine, packaged as 1 mL of solution in a single-use clear glass vial or 30 mL of solution in a multiple-dose amber glass vial. In the 1 mL vial, each 1 mL of Adrenalin<span class="Sup">®</span> solution contains 1 mg epinephrine, 9.0 mg sodium chloride, 1.0 mg sodium metabisulfite, hydrochloric acid to adjust pH, and water for injection. In the 30 mL vial, each 1 mL of Adrenalin<span class="Sup">®</span> solution contains 1 mg epinephrine, 9.0 mg sodium chloride, 1.5 mg sodium metabisulfite, hydrochloric acid to adjust pH, 5.4 mg chlorobutanol as a preservative and water for injection. The pH range is 2.2-5.0.</p>
<p>Epinephrine is a sympathomimetic catecholamine. The chemical name of epinephrine is: 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]-, or (-)-3,4-Dihydroxy-α-[2-(methylamino)ethyl]benzyl alcohol.</p>
<p>The chemical structure of epinephrine is:</p>
<div class="Figure">
<a name="id755"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b7a4364-668d-4eb2-a20c-04adc35aabe4&amp;name=adrenaline-01.jpg">
</div>
<p>The molecular weight of epinephrine is 183.2.</p>
<p>Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12    CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Epinephrine acts on both alpha and beta-adrenergic receptors.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, which can lead to loss of intravascular fluid volume and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> and helps alleviate <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> that may occur during <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p>Epinephrine also alleviates <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and may relieve gastrointestinal and genitourinary symptoms associated with <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.</p>
<p>Epinephrine increases glycogenolysis, reduces glucose up take by tissues, and inhibits insulin release in the pancreas, resulting in <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and increased blood lactic acid [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4)</a></span>].</p>
<p>Epinephrine causes <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> when administered intraocularly or parenterally.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">When administered parenterally or intraocularly, epinephrine has a rapid onset and short duration of action.</p>
<p>The extent of human systemic exposure at the labeled intraocular dose has not been evaluated, however, significant systemic concentrations or plasma exposure of epinephrine are not expected when administered intraocularly.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13    NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long- term studies to evaluate the carcinogenic potential of epinephrine have not been conducted.</p>
<p>Epinephrine and other catecholamines have been shown to have mutagenic potential <span class="Italics">in vitro</span>. Epinephrine was positive in the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> bacterial reverse mutation assay, positive in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and negative in the <span class="Italics">in vivo</span> micronucleus assay. Epinephrine is an oxidative mutagen based on the <span class="Italics">E. coli</span> WP2 Mutoxitest bacterial reverse mutation assay. This should not prevent the use of epinephrine under the conditions noted under <span class="Italics"><a href="#S1">Indications and Usage (1)</a>.</span></p>
<p>The potential for epinephrine to impair reproductive performance has not been evaluated, but epinephrine has been shown to decrease implantation in female rabbits dosed subcutaneously with 1.2 mg/kg/day (15-fold the highest human intramuscular or subcutaneous daily dose) during gestation days 3 to 9.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14     CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1  Induction and Maintenance of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> during Intraocular Surgery</h2>
<p class="First">In randomized, controlled studies, patients undergoing routine <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> extraction were evaluated after receiving intraocular irrigation with or without epinephrine diluted up to 1:1,666,666 (0.6 mcg/mL). Patients have also been evaluated after receiving bolus intracameral injections of epinephrine diluted between 1:25,000 (40 mcg/mL) and 1:400,000 (2.5 mcg/mL).</p>
<p>In patients with similar pupil diameters at baseline, with or without the use of preoperative mydriatic agents, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> was maintained better in the eyes receiving epinephrine by an average of one to two millimeters in pupil diameter. Pupil constriction to 5mm or less occurred more often in the patients not receiving epinephrine.</p>
<p>Mean pulse rate and blood pressure showed no significant difference between patients receiving epinephrine and controls and there was no increased incidence of ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> in patients receiving epinephrine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16    HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">Adrenalin<span class="Sup">®</span> 1 mL Single-Use Vials:</span></p>
<dl>
<dt> </dt>
<dd>Each carton contains 25 single-use vials containing 1 mL Adrenalin<span class="Sup">®</span> (epinephrine injection, USP) solution 1 mg/mL (1:1000) in a 3 mL clear glass vial.</dd>
<dt> </dt>
<dd>NDC 42023-159-25      1 mL vial</dd>
</dl>
<p><span class="Bold">Adrenalin<span class="Sup">®</span> 30 mL Multi-Dose Vials:</span></p>
<dl>
<dt> </dt>
<dd>Each carton contains either 1 multiple-dose vial or 10 multiple-dose vials containing 30 mL Adrenalin<span class="Sup">®</span> (epinephrine injection, USP) solution 1 mg/mL (1:1000) in a 36 mL amber glass vial.</dd>
<dt> </dt>
<dd>NDC 42023-168-01      30 mL vial, pack of 1</dd>
<dt> </dt>
<dd>NDC 42023-168-10      30 mL vial, pack of 10</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_86fe6788-e93e-4956-8308-e909de95bba5"></a><a name="section-14.1"></a><p></p>
<p class="First">Vial and contents must be discarded 30 days after initial use.</p>
<p>Store between 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.)  Epinephrine is light sensitive. Protect from light and freezing.</p>
<p>Inspect visually for particulate matter and discoloration prior to administration. Do not use the solution if it is colored or cloudy, or if it contains particulate matter.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17    PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients or their caregivers about common adverse reactions associated with the use of epinephrine including an increase in heart rate, the sensation of a more forceful heartbeat, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>. These symptoms and signs usually subside rapidly, especially with rest, quiet and recumbent positioning.</p>
<p>Warn patients with a good response to initial treatment about the possibility of recurrence of symptoms and instruct patients to obtain proper medical attention if symptoms return.</p>
<p>Warn patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> that they may develop increased blood glucose levels following epinephrine administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_583657f0-7234-4240-9b08-3b41d39e000b"></a><a name="section-16"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">Par Pharmaceutical Companies, Inc.</span><br>Spring Valley, NY 10977</p>
<p>Adrenalin<span class="Sup">®</span> is a registered trademark of Par Sterile Products, LLC (Spring Valley, NY).<br>Registered Trademark No 53,934</p>
<p>I02/15</p>
<p>OS159J-01-90-01</p>
<p>3003302B</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_ce905406-12ea-48a4-a988-33f3713ccb75"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1 mL Vial Label</span></p>
<p>NDC 42023-159-25<br>Rx Only</p>
<p><span class="Bold">Adrenalin<span class="Sup">®</span></span><br>(epinephrine<br>injection, USP)</p>
<p><span class="Bold">1 mg/mL</span></p>
<p><span class="Bold">1:1000</span></p>
<p>1 mL Solution in a 3 mL<br>Single-Use Vial</p>
<div class="Figure">
<a name="id928"></a><img alt="PRINCIPAL DISPLAY PANEL - 1 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b7a4364-668d-4eb2-a20c-04adc35aabe4&amp;name=adrenaline-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_34c9e3c7-ed8a-4734-a81a-268d30081196"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30 mL Vial Label</span></p>
<p>NDC 42023-168-01<br>Rx Only</p>
<p><span class="Bold">Adrenalin<span class="Sup">®</span></span><br>(epinephrine<br>injection, USP)</p>
<p><span class="Bold">1 mg/mL</span></p>
<p><span class="Bold">(30 mg/30 mL)</span><br><span class="Bold">1:1000</span></p>
<p><span class="Bold">For Intramuscular or</span><br><span class="Bold">Subcutaneous Use</span></p>
<p>Not for Ophthalmic Use</p>
<p>30 mL Multiple Dose Vial</p>
<div class="Figure">
<a name="id960"></a><img alt="PRINCIPAL DISPLAY PANEL - 30 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b7a4364-668d-4eb2-a20c-04adc35aabe4&amp;name=adrenaline-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADRENALIN 		
					</strong><br><span class="contentTableReg">epinephrine injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42023-159</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAOCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>epinephrine</strong> (epinephrine) </td>
<td class="formItem">epinephrine</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium metabisulfite</strong></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42023-159-25</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204200</td>
<td class="formItem">07/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADRENALIN 		
					</strong><br><span class="contentTableReg">epinephrine injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42023-168</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>epinephrine</strong> (epinephrine) </td>
<td class="formItem">epinephrine</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium metabisulfite</strong></td>
<td class="formItem">1.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>chlorobutanol</strong></td>
<td class="formItem">5.4 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42023-168-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:42023-168-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204640</td>
<td class="formItem">03/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Par Pharmaceutical, Inc.
							(092733690)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Par Pharmaceutical, Inc. (092733690)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cd5c1f4f-d9ba-4a2d-9740-5b44c1a17794</div>
<div>Set id: 3b7a4364-668d-4eb2-a20c-04adc35aabe4</div>
<div>Version: 3</div>
<div>Effective Time: 20150918</div>
</div>
</div> <div class="DistributorName">Par Pharmaceutical, Inc.</div></p>
</body></html>
